Zhang Dongxu, Liang Pu, Xia Bowen, Zhang Xin, Hu Xiaopeng
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongti South Road, Beijing, China.
Institute of Urology, Capital Medical University, Beijing, China.
Pain Ther. 2023 Aug;12(4):1079-1093. doi: 10.1007/s40122-023-00530-0. Epub 2023 Jun 7.
Renal colic is one of the most common urological emergencies, and is usually caused by ureteral colic spasms. Pain management in renal colic remains the central focus of emergency treatment. The purpose of this meta-analysis is to identify the efficacy and safety of ketamine versus opioids in the treatment of patients with renal colic.
We searched PubMed, EMBASE, Cochrane Library, and Web of Science databases for published randomized controlled trials (RCTs) that referred to the use of ketamine and opioids for patients with renal colic. The methodology was based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The mean difference (MD) or odds ratio (OR) with a 95% confidence interval (CI) was used to analyze the data. The results were pooled using a fixed-effects model or random-effects model. The primary outcome measure was patient-reported pain scores 5, 15, 30, and 60 min after drug administration. The secondary outcome measure was side effects.
The data analysis revealed that ketamine was similar to opioids in pain intensity at the time of 5 min post-dose (MD = - 0.40, 95% CI - 1.82 to 1.01, P = 0.57), 15 min post-dose (MD = - 0.15, 95% CI - 0.82 to 0.52, P = 0.67), 30 min post-dose (MD = 0.38, 95% CI - 0.25 to 1.01, P = 0.24). Also, the pain score of ketamine was better than that of opioids at 60 min after administration (MD = - 0.12, 95% CI - 0.22 to - 0.02, P = 0.02). As for safety, the ketamine group was linked to a significant decrease in the incidence of hypotensive (OR = 0.08, 95% CI 0.01-0.65, P = 0.02). The two groups did not statistically differ in the incidence of nausea, vomiting, and dizziness.
Compared with opioids, ketamine showed a longer duration of analgesia in renal colic, with satisfactory safety.
The PROSPERO registration number is CRD42022355246.
肾绞痛是最常见的泌尿外科急症之一,通常由输尿管绞痛痉挛引起。肾绞痛的疼痛管理仍然是急诊治疗的核心重点。本荟萃分析的目的是确定氯胺酮与阿片类药物治疗肾绞痛患者的疗效和安全性。
我们在PubMed、EMBASE、Cochrane图书馆和Web of Science数据库中搜索已发表的随机对照试验(RCT),这些试验涉及氯胺酮和阿片类药物在肾绞痛患者中的使用。该方法基于系统评价和荟萃分析的首选报告项目(PRISMA)指南。采用95%置信区间(CI)的平均差(MD)或比值比(OR)来分析数据。结果采用固定效应模型或随机效应模型进行汇总。主要结局指标是患者报告的给药后5、15、30和60分钟的疼痛评分。次要结局指标是副作用。
数据分析显示,氯胺酮在给药后5分钟(MD = -0.40,95%CI -1.82至1.01,P = 0.57)、15分钟(MD = -0.15,95%CI -0.82至0.52,P = 0.67)、30分钟(MD = 0.38,95%CI -0.25至1.01,P = 0.24)时的疼痛强度与阿片类药物相似。此外,氯胺酮在给药后60分钟的疼痛评分优于阿片类药物(MD = -0.12,95%CI -0.22至-0.02,P = 0.02)。在安全性方面,氯胺酮组与低血压发生率显著降低相关(OR = 0.08,95%CI 0.01 - 0.65,P = 0.02)。两组在恶心、呕吐和头晕的发生率上无统计学差异。
与阿片类药物相比,氯胺酮在肾绞痛中的镇痛持续时间更长,安全性良好。
PROSPERO注册号为CRD42022355246。